

PAHO's Regional Revolving Funds

A health cooperation success story

The Funds' contributions include:



Disease elimination:
Polio, rubella, measles



New vaccines: Rotavirus, HPV, pneumococcal



95% of vaccines for National Immunization Programs



130 million people received at least one vaccine dose in 2022 and 2023



Over 400 million vaccines, syringes and other supplies for immunization in 2022



Health products for 17 diseases that are part of the Elimination Initiative

Everyone benefits: Member States, suppliers, and partners

Benefits for Member States are: facilitated processes – including timely demand planning, international bids, international logistics; lower prices and better conditions through the economy of scale; timely, reliable, and quality assured supply; an alignment with technical recommendations; and a line of credit, which allows countries to advance financing for 60 days with no interest to ensure the continuity of safe, effective, and quality health care supplies.

Incorporating digital technologies for higher transparency and efficiency

In alignment with PAHO's digital transformation to improve decision-making at all levels of healthcare, the Funds launched in July 2023 the first digital demand planning module to replace excel forms, provide real-time and easy access to information, and process integration including requests tracking from demand planning to receipt of shipment. Digital solutions will add transparency to procurement and delivery processes to countries, and monitoring for delivery delays and supply chain risks. Cloud-based tools also developed in 2023 included a risk-monitoring tool and a collaboration portal between PAHO and ministries of health that was piloted during the pandemic.



The Regional Revolving Funds have contributed to the prevention, control, and elimination of diseases across the Americas

PAHO's Regional Revolving Funds in numbers, 2022-2023

The Pan American Health Organization (PAHO)'s Regional Revolving Funds (RRFs) are technical cooperation mechanisms that enable the Americas to equitably and timely access quality vaccines, essential medicines, and public health supplies.

When countries work together, they achieve benefits for all: through pooled procurement and planning their demand together, Member States obtain affordable prices, securing around 50% in savings for vaccines and public health supplies; benefitting around 180 million people in the past two years alone.

PAHO's RRFs comprise the Revolving Fund for Access to Vaccines and the Strategic Fund for Public Health Supplies.

The RRFs are key to the Americas' impressive record of addressing public health demands by responding rapidly, implementing critical interventions for access to health technologies, and supporting disease elimination.

The Funds' product portfolio includes medicines for communicable and noncommunicable diseases as well as neglected diseases; diagnostic kits and medical equipment such as rapid tests for HIV, malaria, leishmaniasis and more; vector control supplies such as insecticides and long-lasting insecticidal nets; and vaccines and related supplies such as safety boxes, immunoglobulins, and cold chain equipment.

The RRFs have also contributed to the introduction of new health supplies in countries, as well as the response to recent health emergencies such as COVID-19 and mpox. Moreover, the Funds are central to achieving the renewed Disease Elimination Initiative's targets.



60 years
of combined
experience working
across borders



2nd largest
health sector procurer in the
UN system during 2022/23



Over USD 1.8 billion
of vaccines, medicines
and health supplies

23 million
treatments and
diagnostic tests

460 million
vaccine doses

50% of savings
in purchase of vaccines,
biologics, and cold chain
equipment

50% decrease in the
prices of key antiretroviral
treatments in 2023
compared to 2018 prices



1.6 million units
of cold chain equipment

USD 75 is now the cost
for a hepatitis C test
and treatment package
since 2023

90% price reduction
for key antidiabetic
medicines compared to
the last biennium

OPS/OMS



Distribución Gratuita Aprobado por el M.P.P.S

LOTE NO.:
FECHA ELAB:
FECHA VENC:
PESO BRUTO: 13.7kg
PESO NETO: 12.7kg
Dimension: 44.5x30x23.2 (cm)